Introduction
In 1982, the US Congress passed the Orphan Drug Act, which was signed into law by President Ronald Reagan in 1983, giving tax and exclusivity incentives to companies that invest in drug development programs for rare diseases-defined as diseases affecting fewer than 200,000 patients [1, 2] . This law ended up serving as a model for Japan, which passed the Orphan Drug Law in 1993, and the European Union (EU), which passed its own Orphan Drug Legislation in 1999 [3] . Interestingly, although the Orphan Drug Act was the pioneer, the definition of an orphan disease is not universal, as the European Union (EU) considers a disease with a prevalence of 5 or fewer cases per 10,000 individuals to be orphaned [2] . These laws have had both a positive and an unintended negative effect on the approach of the pharmaceutical industry to rare disease drug development and marketing. Although rare disease oriented therapies were not expected to yield great profit, in recent years, the pricing set by pharmaceutical companies for some efficient rare genetic disease drugs-including some types of cancers-have approached "blockbuster" status (with annual sales close to 1 billion US dollars) and have been recently called "niche-buster" drugs [4] . In fact, since the Orphan Drug Act, more than 300 drugs have been developed and approved for orphan diseases, whereas fewer than 10 drugs had been approved by the Food and Drug Administration (FDA) in the 10 years prior to the passing of the Act [2] . Neither the Hatch-Waxman Act of 1984-passed by the US Congress with the goal to encourage the marketing of generic medicines and reduce health-care cost-nor the Biologics Price Competition Act of 2009-signed into law by president Barrack Obama in 2010-have managed to mitigate the high prices of orphan disease drugs. It is noteworthy to mention that this is partially due to the high rate of failure of drug development and the costs associated with a high failure rate. For instance, for a specific disease, approximately 250 new chemical entities (NCEs) out of 10,000 may make it to animal testing, and only 5-10 of these may get tested in humans where only 1 or 2 of these investigational new drugs (INDs) may be marketable [5] . Pharmaceutical companies also attempt to recuperate their investment in an orphan drug through high prices since they cannot obtain profits through volume of sales as they would with drugs that target wider-spread diseases such as diabetes, asthma, or high cholesterol. Taking that into account, for example, treatment with the Genzyme drug imiglucerase, an enzyme replacement therapy (ERT) developed to treat Gaucher's disease, might cost as much as US$400,000 per year for an adult patient [6] . Similar costs are observed for treatment of patients with Genzyme's Aldurazyme, an ERT made to treat mucopolysaccharidosis type I. Consequently, one of the biggest criticisms of the Orphan Drug Act is the high cost of treatment.
Orphan product exclusivity-exclusive marketing rights for an extended period (7 years in the USA, 10 years in the European Union and Japan, and 5 years in Australia)-is crucial to keep pharmaceutical companies interested in developing drugs for rare disorders. There are many advantages to being designated an orphan drug. Most importantly and enticing to the pharmaceutical industry is the fact that unlike patent requirements that are stringent and require a drug to be novel and nonobvious to someone trained in the art, the only requirements needed for marketing exclusivity of an orphan drug are that the drug be orphan-designated, safe and approved for the indication. Additionally, orphan drug marketing exclusivity starts the day the FDA approves the drug unlike patented drugs where protection starts early in the development process, years prior to FDA approval. An orphan drug thus often has more years of protected marketing. Furthermore, "obvious" drugs that would typically not be patentable can be designated orphan drugs and protected. Examples such as zinc (for Wilson's disease), caffeine (for apnea of prematurity), albuterol (for prevention of paralysis due to spinal cord injury), and ascorbic acid (for Charcot-Marie-Tooth disease) are among a few nonpatentable drugs that can be found in the orphan drug literature [7] . A database including the complete list of orphan drugs designations and their related indication approvals can be queried on the US Food and Drug Administration (FDA) website: http://www.accessdata. fda.gov/scripts/opdlisting/oopd/index.cfm.
Without exclusivity rights companies such as Amgen, Genzyme, and Genentech whose first marketed products were orphan drugs would not likely be as successful as they are today. By the same token, without the lucrative incentives allowed to an orphan-product designation, efficient drugs such as those mentioned above as well as drugs for some of the rarest diseases such as severe combined immunodeficiency associated with a deficiency of adenosine deaminase (SCID-ADA) and tyrosinaemia type-I would not exist [6, 8, 9] . Hence, there is a symbiotic relationship among orphan disease drug development, patients, and pharmaceutical companies. However, few companies actually want to take the risk of investing in orphan disease drug R&D, thus creating a vacuum in this space. Recently, foundations have gotten involved, filling some of the support gaps for orphan disease drug R&D through personalized medicine, academic drug discovery, and nonprofit institutes ( Table 1) .
"Common" orphan diseases and personalized medicine US National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) Office of Rare Diseases Research (ORDR) estimates that approximately 7000 rare diseases have been described to date [10] . In this review, we will use "rare" or "orphan" diseases interchangeably. Advances in genomics, pharmacogenomics, and epigenomics have allowed better definitions and characterizations of orphan diseases, especially those that are monogenic. Consequently, there are approximately 250 new orphan diseases described age diseases (LSDs). These are typically monogenic disorders characterized by lysosomal defects in enzymatic expression and activity, posttranslational modifications, and trafficking of enzymes as well as integral membrane proteins and transporters [12, 13] . These defects cause accumulation of substrates in the lysosomes, leading to tissue damage through still partially understood mechanisms. The most successful US FDA-approved therapies to date have been those based on ERT, which is now considered the standard of care for LSDs. Please see the article by Parenti et al. [17] for a detailed review [14] . Indeed, ever since the successes of ERT administration for Gaucher's disease, investigators and the biotech industry have focused on developing ERTs for rare diseases in which enzyme deficiency is the culprit. Subsequently, ERTs have been developed for numerous LSDs and have either been approved or are in clinical trials for the following diseases: Pompe; Fabry; mucopolysaccharidoses (MPS) types I, II, IIIA, IVA, VI, and VII; lysosomal acid lipase deficiency; alpha-mannosidosis; metachromatic leukodystrophy; neuronal ceroid lipofuscinosis, late infantile (CLN2); and Niemann-Pick disease type B [14] . However, ERT has a number of limitations such as blood-brain barrier permeability, bone penetration and quality of life-route of administration, IV infusion, and high cost of treatment. In light of these limitations, other approaches employed by academia, nonprofit institutes, and some small biotechnology companies include repurposing of small molecule drugs, development of pharmacological chaperones, phenotypic drug every year [2] . Although the cutoff number of 200,000 people defines orphan diseases in the USA, a staggering 20 to 30 million Americans currently suffer from some type of orphan disease [11] . To address this need, personalized medicine has become an intricate, although insufficient, part of funding orphan disease drug discovery. Indeed, although more than 300 drugs have been developed for rare diseases in the past 32 years, this number is a relatively small percentage compared to the close to 7000 designated orphan diseases. As revealed by those numbers, despite the measures and incentives offered to companies by the Orphan Drug Act and others for such diseases, hardly any pharmaceutical companies invest in drug R&D for a disease that may afflict as few as 30 people worldwide. Some diseases are so rare that a specialized physician may end up treating only a single patient for a specific disease per year [11] . Despite those odds, companies such as Genzyme and Genentech-whose first successful drug targeted an orphan disease-invest in orphan disease drug R&D. The often extraordinary success of many blockbuster drugs was not predicted from a business standpoint. It is interesting to speculate what fraction of orphan drugs reached the market due to the insistence of research management [1] .
Orphan disease drug discovery approaches
A group of orphan diseases that has benefited from some successes in academic drug discovery is lysosomal stor- . However, CF has been treated in patients that express the most prevalent ΔF508 mutation of the CF transmembrane conductance regulator (CFTR) with quinazoline derivatives [20] . These compounds serve as pharmacological chaperones that rescue the mis-folding and the trafficking of the ΔF508 mutant protein present in 70 % of CF patients [16] . In the case of CF, the most common molecular defect causes the protein to become trapped in the endoplasmic reticulum and degraded before it can reach the plasma membrane. The channel appears to be fully capable of function, but since it cannot reach the plasma membrane, CF develops. The molecular chaperone approach in this disease aims to allow the mutant CF chloride channels to evade endoplasmic reticulum quality control machinery, route to the plasma membrane, and function normally. This approach is being pursued heavily as a potential curative treatment. Similar approaches are being pursued for hypogonadotropic hypogonadism [21] , LSDs [17] , and others.
Phenotypic drug screening
Whereas many orphan indications result from rare genetic mutations, which can be identified and a target provided, there are others, such as autoimmune disease, with a much more complex biology or completely unknown etiology. In cases such as these, and without a clear molecular target, a phenotypic approach to drug discovery needs to be pursued. Typically, phenotypic screening is avoided due to the challenges of the development process. For example, it is difficult to increase the potency of a compound in a medicinal chemistry effort if the molecular target is unknown, that is to say, an "optimization" may result in more than one activity in the cell and the resulting activities may offset each other. Despite these drawbacks, phenotypic screening has yielded 28 new molecular entities that were discovered and developed in the years 1999-2008 [22] . Probably, the best use of phenotypic screening is in drug repositioning where currently available FDA-approved drugs are tested to provide a resulting phenotype in the cell. The advantages to this approach is that the drug identified will have known human toxicity and drug-like profiles in humans, and the advantages of use can be immediately compared to the disadvantages. Cancer is foremost when it comes to phenotypic screening. The ability of a compound to "melt" cancer cells (cause cell death) is often screened for in academia and industry alike [23] . Vorinostat, an orphan drug for cutaneous T-cell lymphoma, was discovered to induce myeloid differentiation and then subsequently identified as a broad spectrum histone deacetylase (HDAC) inhibitor [24] .
Personalized medicine
Personalized medicine is the tailoring of medicine to an individual patient. Traditionally, this has meant that a screening, improvement of antibody therapeutics, and advancement in gene therapy.
Small molecule strategies

FDA-approved drug repurposing
Repurposing FDA-approved drugs offers several advantages over novel compounds that have not yet been shown to be efficacious and safe in humans. Such compounds allow the possibility of rapid treatment with drugs where the safety profile is well established. Additionally, a repurposed compound is oftentimes no longer under patent protection, and generic versions are available, thus potentially diminishing treatment cost to the patient. The "Rare Diseases Repurposing Database" [15] describes 236 drugs that have been granted orphan product status although they have not been formally allowed to be marketed for these rare diseases per se [15] . Such tools are still rare, and screening FDA-approved drugs to assess their potential as treatments for orphan diseases requires tremendous expertise and work.
Molecular and pharmacological chaperones
Molecular chaperones (pharmacological chaperones, pharmacoperones) are compounds, usually but not exclusively small molecules, directed toward a protein target, which has a folding defect that causes the protein to be defective [16] [17] [18] . Molecular chaperones can also increase the activity of truncated proteins but will typically have little effect on proteins where large truncations have removed major functional domains such as enzyme catalytic sites or transmembrane domains. However, in the case where there is a point mutation or where the most important functional domains remain, a chaperone approach can serve to increase protein function substantially. Pharmacological chaperones have recently emerged as potential treatments for orphan diseases such as the LSDs: Gaucher's, Fabry, Pompe, and gangliosidosis. Please see Parenti (2009) for a comprehensive review [16] . As mentioned above, some of the limitations of ERT, the current standard of care for the aforementioned diseases, include low biodistribution, low bloodbrain barrier (BBB) permeability, and increased immune response to the corrective enzyme. Small molecule compound chaperones represent an alternative therapeutic avenue to circumvent these limitations. Consequently, other than their use in LSDs, pharmacological chaperones have been proposed as treatments for loss-of-function genetic diseases such as cystic fibrosis (CF), phenylketonuria (PKU), autosomal dominant retinitis pigmentosa, nephrogenic diabetes insipidus, hypogonadotropic hypogonadism, and hyperoxaluria type I [16, 19] . These chaperones can ameliorate the disease at different levels, from mutated enzyme trafficking/stability to enzyme conformation/folding and catalytic activity. There have been disappointments in this approach, such as the this approach. Among the LSDs, for instance, gene therapy is undergoing clinical trial for the following diseases: Gaucher's type 1; Fabry; metachromatic leukodystrophy (late infantile); mucopolysaccharidosis II, IIIA, and IIIB; neuronal ceroid lipofuscinosis, late infantile (CLN2); and Pompe disease [14] . This is among the most exciting and active areas for research that could benefit rare disease patients.
Natural history studies
Natural history studies (NHS) are necessary in both rare and prevalent diseases to define both disease and disease progression, where patients are followed ideally before the disease is apparent. The course and effects of the disease are documented in order to understand the disease. A major hurdle is the development of biomarker assays that allow monitoring of disease progression. This is of particular interest in orphan diseases as we move to defined patient populations in early clinical development. Such quantitative biomarkers play an important role since the spectrum of the disease may appear very differently in a relatively small patient population and many rare diseases are chronic. There tends to be an inverse correlation with patient population and level of understanding of a disease. Added to this is that with few or no current treatment options, it is difficult to categorize patients into treatment groups, so especially in rare disorders without any obvious etiology, NHS serve to inform a clinical trial and be useful in developing inclusion criteria. In an ideal case, an NHS will help identify biomarkers that can be used as outcome measures to increase the power of a clinical trial. NHS are thus a key component of a drug approval. The added benefit to patients with a rare disease is that due to the requirement to include NHS in an FDA application, a rare disease may actually become much more defined for the patient and for treating physicians to improve treatment options and standard of care [26, 27] .
Challenges
There are numerous challenges in attempting to find treatments for orphan diseases aside from the scarcity of the patient population. Access to patients and patient samples, population size and heterogeneity (age, sex, quality of therapy, etc.), naïve vs. treated patients, mutation severity spectrum, age of onset, and increasing the activity or expression of enzymes (it is much easier to inhibit) are all surmountable challenges, but challenges nonetheless.
Preclinical studies
In prevalent diseases such as Alzheimer's or Parkinson's, cell and animal models are oftentimes generpatient's disease symptoms and pathophysiology was used to dictate which medicines to deliver. However, in recent times techniques such as DNA and RNA sequencing have allowed the ability to utilize molecular biomarkers to inform treatment options termed as a pharmacogenomics approach. For example, in cancers, sequencing the cancer cell may reveal a mutation in a pathway where there is a known drugs to treat such a mutational landscape. This kind of approach is elegant and can save the patient from undergoing harsh treatments that would be predicted to fail and also potentially uncover novel treatments that would not typically be part of the standard of care. One of the most promising applications of personalized medicine, yet to be realized, may be in the undiagnosed patient populations where a disease cannot even be ascribed. Syndromes such as these may benefit from a personalized approach where patient symptomatology, treatment outcomes, and pharmacogenomics are combined to inform treatment options, especially in cases where no treatment options exist. Indeed, for ultrarare diseases, a physician may have only a single patient and in such a case rely on experiencebased medicine to treat symptoms. The ability to enroll such a patient in a personalized medicine program to identify potential therapeutic avenues could be invaluable and may also provide information for the identification of a new disease, diseased patient population, and even biomarkers for disease progression and treatment outcomes [25] .
Gene Therapy
Monogenic rare diseases hold among the best potential for gene therapy approaches because the gene causing the defect(s) can be directly targeted. Furthermore, in severe diseases such as some aggressive cancers, the potential benefits outweigh the potential drawback of using a gene therapy experimental approach. In LSDs, for example, gene therapy can be used to either increase or restore defective enzyme activity in patients' cells and tissues by delivering a wild-type copy of the defective gene, or a reengineered copy where the defective gene is "corrected" and reintroduced to the patient. A strategy for the former is to systemically deliver, under the control of a ubiquitous promoter, the therapeutic gene in order to allow synthesis of the wild-type protein in the patient. A strategy for the latter is to collect patient bone marrow cells, transduce them ex vivo, and reintroduce the "genetically corrected" cells [14] . This sort of bone marrow transplant may have a reduced risk of immune reaction by the patient. One gene therapy for a rare disorder currently has European approval: alipogene tiparvovec (Glyerba) has been approved for lipoprotein lipase deficiency. This US$1.6 million treatment is likely to become the world's most expensive drug. Long-term and side effects are still unclear for this and other gene therapy approaches, making this a risky approach. However, it is not out of the realm of possibility that with the first wave of approvals and improvement in the technology that all single gene rare diseases will be addressed in part with
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Alzheimer's has a great deal of funding where rare diseases typically do not. There are several efforts to address this disparity, such the National Organization for Rare Diseases (NORD), which has been successful in the past at lobbying the US Congress for improvements to the Orphan Drug Act. NORD comprises more than 2000 different organizations representing specific rare diseases, and they provide funds through a small grant program to help develop drugs/treatment for orphan diseases [11] . Such grants can help with the collection of pilot data in order to apply for larger financial support through the NIH or other mechanisms. The NIH also has programs to help fund rare disease research at higher rates, and also the NIH official policy is to not consider the number of patients affected when considering funding an application. This helps to balance the funding. Another solution to this problem resides in patient advocacy groups and foundations, which focus on a particular rare disease and often also serve to unite researchers within an area. It has also been encouraging that as in recent years several funding sources become more competitive, the rare diseases appear to maintain their funding, and perhaps even gained ground. Along the same lines, the FDA Office of Orphan Products Development (OPD) is the largest funding source for clinical grants that helps bridge the gap between basic research, clinical development, and marketing approval [3] . These grants cover portions of phases I, II, and III clinical trials and do not consider preclinical development. The OPD grants are especially useful for academic researchers. These academically developed drugs can then be licensed to pharmaceutical companies for commercialization purposes. This method may reduce the final cost of treatment for patients.
Conclusions and recommendations
Although the vast majority of rare diseases have no treatments, the past 20 years have shown that rare diseases represent a ripe area for research and development with a high potential for uncovering novel treatments and achieving commercial success. Rare disease legislation has stimulated these areas and the field appears to be as strong as ever. With emerging technologies and increased understanding of epigenetics, epigenomics, and pharmaco-epigenetics, new methods of undertaking therapeutics discovery for orphan diseases are imminent. Epigenetics approaches offer the possibility to modulate (upregulate or downregulate) gene expression with small molecules without the need for gene therapy. Such methods are already being developed and potentially coming to fruition against MPS I and other rare diseases [30, 31] .
Orphan diseases and especially monogenic diseases etiology and pathogenesis can be more straightforward than polygenic diseases such as Alzheimer's, and as a result the drug discovery process can be quite streamlined. Indeed, academic centers are cropping up that ated by teams of scientists to test potential treatments. Although cell models are also frequent in rare diseases, it is much more difficult to encounter animal models in those because of the long lead time and expertise needed to generate them. Many experts rely on in vitro or ex vivo studies to test potential drugs. Indeed, a gold standard model currently used by pharmaceutical companies and academia is skin fibroblast cells isolated from patients. Another frequently used model is lymphocytes obtained from patients, and from which induced pluripotent stem cells (IPSCs) can easily be derived. However, it is difficult to file an IND application solely based on in vitro data. The US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) has a set of guidelines that they recommend for exploratory IND applications with limited but well-designed studies [28] . Although these guidelines can be used for an IND application targeting any disease, it provides a streamline approach that is useful for orphan diseases, considering the limited supply of samples. For example, although preclinical studies have to describe in detail the chemical properties of the candidate drug, including toxicology, pharmacokinetics, dosage, and route of administration, fewer animals, fewer doses, and shorter exposures can be used to apply for an exploratory IND compared to the regular one.
Clinical trials
Typical randomized clinical trials are difficult to conduct in orphan diseases due to the scarcity of patients. One also faces possible ethical questions if small cohorts of patients are treated with placebos for an aggressive disease when a possible experimental drug could have saved their lives. A possibility to meet this challenge is to use each patient as his/her own control. These are often "N of 1" trials or multiple crossover trials [29] . These types of trials have the advantage that each patient is exposed to both placebo and treatment, but it becomes more difficult to extrapolate the results due to intra-and extra-individual variances. Another disadvantage of the crossover and "N of 1" trial formats is that outcome variables need to be stable or linearly progressive to be certain that the treatment is working. Surrogate biomarkers have to be determined and quantitative biomarker assays have to be reliable in order to conduct an orphan disease clinical trial.
Funding
Although the issue of commercial return on investment has been incentivized with legislation and there are several for-profit companies with a robust business model, there remains the issue of funding, especially in early preclinical work. It can take as many resources to uncover the pathophysiology of a rare disease as it would for a common disease such as Alzheimer's. Yet, are taking the lead in the drug discovery and development process. This is demonstrated by approximately 90 % of all new indications for previously FDA-approved drugs resulting from collaborations with academic institutions (including federal laboratories and universities) [40] . The potential upside for companies to enter into rare disease therapeutic areas has been apparent for a number of years, yet there is still a disconnect in publicprivate partnerships, which may be a result of an overall lower number of groups working on any one particular disease. Thus, pushing funding to rare diseases should be a priority, and new models for commercial interests funding early work should be considered. With a higher chance for success and legislation in place to ensure commercial benefit, the public-private partnerships are likely to be actually more fruitful than the same partnerships would be for common diseases. Disease-specific foundations and patient groups are the obvious facilitators of this kind of interaction and may also serve to provide patient information for clinical trials recruitment.
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